Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Innovatus Capital Partners

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 15
Average round size
info
The average size of a deal this fund participated in
$73M
Portfolio companies 11
Rounds per year 2.50
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.27
Exits 5
Key employees 8

Areas of investment

  • Biotechnology
  • Medical
  • Health Care
  • Genetics
  • Health Diagnostics
Summary

The main department of described VC is located in the New York. The fund was located in North America if to be more exact in United States.

The overall number of key employees were 8.

The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Innovatus Capital Partners, startups are often financed by CRG L.P., Windham Venture Partners, Tullis Health Investors. The meaningful sponsors for the fund in investment in the same round are WuXi NextCODE, Telegraph Hill Partners, TPG Biotech.

The common things for fund are deals in the range of 10 - 50 millions dollars. Opposing the other organizations, this Innovatus Capital Partners works on 21 percentage points more the average amount of lead investments. Speaking about the real fund results, this VC is 55 percentage points more often commits exit comparing to other organizations. The top activity for fund was in 2019. The fund is generally included in less than 2 deals every year.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline DNAnexus, Personal Genome Diagnostics (PGD) The fund has no exact preference in some founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Biotechnology, Bioinformatics. Besides, a startup requires to be at the age of 11-15 years to receive the investment from the fund.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Allstate Strategic Ventures Illinois, Northbrook, United States
CIMB Kuala Lumpur, Malaysia
Columbia Ventures Corporation -
COPIC Companies -
Explore Ventures -
Funderbeam England, London, United Kingdom
Gentera Distrito Federal, Mexico, Mexico City
Guokai Ronghua -
Hengying Capital Beijing, Beijing, China
Impact Venture England, London, United Kingdom
K5 Global California, Los Angeles, United States
LUMO labs Eindhoven, Noord-Brabant, The Netherlands
Musashi Securities Japan, Saitama, Saitama Prefecture
PJC Capital Minneapolis, Minnesota, United States
prominent venture capital -
Qingkong Jinxin Blue Microbiology Fund -
Surround Ventures New York, New York, United States
The Rahn Group Minneapolis, Minnesota, United States
U.S. Army Combat Capabilities Development Command Army Research Laboratory Louisiana, Maryland, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Eiger BioPharmaceuticals

Biotechnology
Health Care
Medical
$5M07 Jun 2022 California, United States

DNAnexus

Bioinformatics
Biotechnology
Cloud Computing
Genetics
Medical
$200M08 Mar 2022 Mountain View, California, United States

Apollo Endosurgery

Biotechnology
Health Care
Medical Device
$35M21 Dec 2021 Austin, Texas, United States

Geneoscopy

Biotechnology
Genetics
Health Care
Health Diagnostics
$105M16 Nov 2021 City of Saint Louis, Missouri, United States

Exagen

Biotechnology
Genetics
Health Care
Health Diagnostics
Medical
$27M25 Oct 2021 Vista, California, United States

Spacial

Construction
Real Estate
Residential
$2M13 Sep 2021 -

Imperative Care

Health Care
Medical
Medical Device
$260M15 Jul 2021 California, United States

Personal Genome Diagnostics

Analytics
Bioinformatics
Biotechnology
Genetics
Health Diagnostics
Medical
$103M10 Feb 2021 Baltimore, Maryland, United States

Akoya Biosciences

Biotechnology
Health Care
Life Science
$50M05 Dec 2019 Marlborough, Massachusetts, United States
News
Imperative Care Raises $260 Million to Advance Innovations that Elevate Stroke Care

– Imperative Care, Inc. announced that it has closed a $260m Series D financing led by D1 Capital Partners.
– New investors HealthCor Investments LLC and Innovatus Capital Partners also joined the round. Existing Imperative Care investors Ally Bridge Group, Bain Capital Life Sciences, Ascension Ventures, Delos Capital, Rock Springs Capital, and Amed Ventures participated in the financing.
– James Rogers from D1 will join Imperative Care’s Board of Directors.
– Proceeds from the financing will be used to support ongoing commercialization and development of a wide range of Imperative Care’s technologies in the broad continuum of stroke care, as well as to create a strategic network of wholly owned development subsidiaries in a number of areas of synergy.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Innovatus Capital Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: